• Tonix Pharmaceuticals will present a Phase 3 TONMYA analysis October 27, 2026, at the IASP World Congress on Pain in Bangkok.
• The analysis indicates reduced fibromyalgia impact on physical symptoms and functional ability.
• TONMYA received FDA approval for adult fibromyalgia August 15, 2025; its U.S. commercial launch followed November 17, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190700PRIMZONEFULLFEED9847773) on October 19, 2026, and is solely responsible for the information contained therein.